Three-dose vaccination elicits neutralising antibodies against omicron

Affiliations

¹ The Francis Crick Institute, London NW1 1AT, UK.
² The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
³ Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴ University College London, London, UK.
⁵ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
⁷ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
⁸ The Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.

Mary Wu et al. Lancet. 2022.

. 2022 Feb 19;399(10326):715-717.

doi: 10.1016/S0140-6736(22)00092-7. Epub 2022 Jan 19.

¹ The Francis Crick Institute, London NW1 1AT, UK.
² The Francis Crick Institute, London NW1 1AT, UK; National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK.
³ Worldwide Influenza Centre, The Francis Crick Institute, London, UK.
⁴ University College London, London, UK.
⁵ The Francis Crick Institute, London NW1 1AT, UK; University College London, London, UK.
⁶ The Francis Crick Institute, London NW1 1AT, UK; Department of Infectious Disease, St Mary's Hospital, Imperial College London, London, UK.
⁷ National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre and NIHR UCLH Clinical Research Facility, London, UK; University College London, London, UK.
⁸ The Francis Crick Institute, London NW1 1AT, UK. Electronic address: david.bauer@crick.ac.uk.

No abstract available

References

1. Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2021 doi: 10.1038/d41586-021-03824-5. published online Dec 23. - DOI - PMC - PubMed
1. Cromer D, Steain M, Reynaldi A, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a meta-analysis. Lancet Microbe. 2021 doi: 10.1016/S2666-5247(21)00267-6. published online Nov 15. - DOI - PMC - PubMed
1. Dejnirattisai W, Shaw RH, Supasa P, et al. Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum. Lancet. 2021 doi: 10.1016/S0140-6736(21)02844-0. published online Dec 20. - DOI - PMC - PubMed
1. Faulkner N, Ng KW, Wu MY, et al. Reduced antibody cross-reactivity following infection with B.1.1.7 than with parental SARS-CoV-2 strains. Elife. 2021;10 doi: 10.7554/eLife.69317. - DOI - PMC - PubMed
1. Katikireddi SV, Cerqueira-Silva T, Vasileiou E, et al. Two-dose ChAdOx1 nCoV-19 vaccine protection against COVID-19 hospital admissions and deaths over time: a retrospective, population-based cohort study in Scotland and Brazil. Lancet. 2021 doi: 10.1016/S0140-6736(21)02754-9. published online Dec 20. - DOI - PMC - PubMed